+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Exportin-1 Protein Inhibitors - Pipeline Insight, 2021

  • ID: 5306351
  • Drug Pipelines
  • March 2021
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Karyopharm Therapeutics
  • Stemline Therapeutics
  • Wigen Biomedicine
  • MORE
This “Exportin-1 protein inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 6+ pipeline drugs in Exportin-1 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Exportin-1 protein inhibitors Understanding

Exportin-1 protein inhibitors: Overview

Exportin 1 (XPO1), also known as chromosomal region maintenance 1 (CRM1), is a eukaryotic protein that mediates the nuclear export of various proteins and RNAs. Exportin-1 recognizes certain RNAs, including viral mRNAs, cellular mRNAs, and small nuclear RNAs (snRNAs), and exports them from the nucleus to the cytoplasm. Exportin 1 affinity for cargo proteins is regulated by binding of Ran-GTP in the nucleus, and Ran-GAP-mediated Ran-GTP hydrolysis releases the cargo proteins in the cytoplasm. Exportin 1 cargo proteins also include tumor suppressor proteins (TSPs), apoptosis inducers and cell cycle regulators. Various haematologic malignancies and solid tumors have been discovered to be dependent on Exportin 1-mediated nuclear export for their survival. Because of this property, exportin 1 is being exploited as an oncology drug target.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Exportin-1 protein inhibitors R&D. The therapies under development are focused on novel approaches for Exportin-1 protein inhibitors.

Exportin-1 protein inhibitors Emerging Drugs Chapters

This segment of the Exportin-1 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Exportin-1 protein inhibitors Emerging Drugs

Selinexor: Karyopharm Therapeutics

Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. The drug functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. Selinexor, (XPOVIO), has been approved by the United States Food and Drug Administration (FDA) for relapsed or refractory multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Selinexor is also currently being evaluated in ongoing Phase II and III clinical studies in patients with a variety of hematologic and solid tumor malignancies. The drug is in Phase III clinical studies for the treatment of Liposarcoma.

Felezonexor: Stemline Therapeutics

Felezonexor (previously SL 801), is an oral small molecule reversible inhibitor of XPO 1 (exportin 1 protein inhibitor). SL-801 has demonstrated preclinical in vitro and in vivo antitumor activity against a wide array of solid and hematologic cancers. SL-801’s potential ability to reversibly bind XPO1 may offer the possibility to mitigate side effects and help optimize the therapeutic index. The drug is in Phase 1 dose escalation trial in patients with advanced solid tumors.

Exportin-1 protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Exportin-1 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Exportin-1 protein inhibitors

There are approx. 5+ key companies which are developing the Exportin-1 protein inhibitors. The companies which have their Exportin-1 protein inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Karyopharm Therapeutics.

Phases

This report covers around 6+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Exportin-1 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Exportin-1 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Exportin-1 protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exportin-1 protein inhibitors drugs.

Exportin-1 protein inhibitors Report Insights
  • Exportin-1 protein inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Exportin-1 protein inhibitors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Scenario and Emerging Therapies:
  • How many companies are developing Exportin-1 protein inhibitors drugs?
  • How many Exportin-1 protein inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Exportin-1 protein inhibitors?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Exportin-1 protein inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Exportin-1 protein inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Karyopharm Therapeutics
  • Stemline Therapeutics
  • Wigen Biomedicine
Key Products
  • Selinexor
  • BIIB 100
  • Felezonexor
  • WJ 1024
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Karyopharm Therapeutics
  • Stemline Therapeutics
  • Wigen Biomedicine
  • MORE
Introduction

Executive Summary

Exportin-1 protein inhibitors: Overview
  • Structure
  • Mechanism of Action
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Exportin-1 protein inhibitors - Analytical Perspective

In-depth Commercial Assessment
  • Exportin-1 protein inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Exportin-1 protein inhibitors Collaboration Deals
  • Company-Company Collaborations (Licensing/Partnering) Analysis
  • Company-University Collaborations (Licensing/Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Selinexor: Karyopharm Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II/III)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
Felezonexor: Stemline Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
WJ 1024: Wigen Biomedicine
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Exportin-1 protein inhibitors Key Companies

Exportin-1 protein inhibitors Key Products

Exportin-1 protein inhibitors- Unmet Needs

Exportin-1 protein inhibitors- Market Drivers and Barriers

Exportin-1 protein inhibitors- Future Perspectives and Conclusion

Exportin-1 protein inhibitors Analyst Views

Exportin-1 protein inhibitors Key Companies

Appendix

List of Tables
Table 1 Total Products for Exportin-1 protein inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Exportin-1 protein inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
  • Karyopharm Therapeutics
  • Stemline Therapeutics
  • Wigen Biomedicine
Note: Product cover images may vary from those shown
Adroll
adroll